Variagenics

Variagenics was a pioneer in the field of pharmacogenomics, focusing on the application of genetic variation to the drug development process. The company developed proprietary technologies to identify and analyze Single Nucleotide Polymorphisms (SNPs) and haplotypes to predict how patients would respond to specific therapeutic agents. By integrating genetic information into clinical trials, Variagenics aimed to help pharmaceutical partners develop safer and more effective drugs through a personalized medicine approach. Their platform, including the NuMap technology, was designed to identify genetic markers that correlate with drug efficacy and toxicity. The company established significant collaborations with major pharmaceutical firms and research institutions to validate its genomic strategies. In 2003, Variagenics merged with Hyseq Pharmaceuticals to form Nuvelo, marking a significant consolidation in the genomics sector.